Palvella Therapeutics Shares Drop After Q3 Net Loss Widens

MT newswire2026/11/05 14:28

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

10:28 AM EST, 11/05/2026 (MT Newswires) -- Palvella Therapeutics (PVLA) shares dropped 1.7% in morning trading on Thursday after the company posted a wider net loss for Q3. The company reported a Q3 net loss of $1.70 per diluted share, wider than a loss of $1.03 a year earlier. Analysts polled by FactSet expected a loss of $1.78. As of Sept. 30, the company said it had $236.7 million in cash and or cash equivalents on hand. Price: 160.65, Change: -1.63, Percent Change: -1.00

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.

华尔街见闻•2026/11/09 22:12